Jagsonpal [JAGSNPHARM] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison

Jagsonpal Pharmaceuticals Ltd.

NSE
Loading...

Divi's Laboratories Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Jagsonpal Pharmaceuticals Ltd. wins in 10 metrics, Divi's Laboratories Ltd. wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric Jagsonpal Pharmaceuticals Ltd. Divi's Laboratories Ltd. Better
P/E Ratio (TTM) 33.34 67.11 Jagsonpal Pharmaceuticals Ltd.
Price-to-Book Ratio 5.34 10.82 Jagsonpal Pharmaceuticals Ltd.
Debt-to-Equity Ratio 3.50 0.58 Divi's Laboratories Ltd.
PEG Ratio -0.51 4.63 Divi's Laboratories Ltd.
EV/EBITDA 20.20 48.63 Jagsonpal Pharmaceuticals Ltd.
Profit Margin (TTM) 14.53% 24.04% Divi's Laboratories Ltd.
Operating Margin (TTM) 19.03% 29.65% Divi's Laboratories Ltd.
EBITDA Margin (TTM) 19.03% 29.65% Divi's Laboratories Ltd.
Return on Equity 23.07% 14.64% Jagsonpal Pharmaceuticals Ltd.
Return on Assets (TTM) 19.90% 12.94% Jagsonpal Pharmaceuticals Ltd.
Free Cash Flow (TTM) $549.52M $2.15B Divi's Laboratories Ltd.
Dividend Yield 1.01% 0.91% Jagsonpal Pharmaceuticals Ltd.
1-Year Return -9.26% -0.43% Divi's Laboratories Ltd.
Price-to-Sales Ratio (TTM) 4.83 16.18 Jagsonpal Pharmaceuticals Ltd.
Enterprise Value $11.62B $1,635.46B Divi's Laboratories Ltd.
EV/Revenue Ratio 4.13 15.86 Jagsonpal Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 63.74% 63.71% Jagsonpal Pharmaceuticals Ltd.
Revenue per Share (TTM) $42 $388 Divi's Laboratories Ltd.
Earnings per Share (Diluted) $6.06 $93.66 Divi's Laboratories Ltd.
Beta (Stock Volatility) -0.47 0.19 Jagsonpal Pharmaceuticals Ltd.

Jagsonpal Pharmaceuticals Ltd. vs Divi's Laboratories Ltd. Stock Performance Analysis

Loading Price Chart...

JAGSNPHARM
DIVISLAB

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Jagsonpal Pharmaceuticals Ltd.0.81%7.29%3.34%15.99%6.64%10.68%
Divi's Laboratories Ltd.-0.44%1.34%-2.25%8.85%4.11%4.17%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Jagsonpal Pharmaceuticals Ltd.-9.26%40.83%241.72%1,222.84%3,458.75%2,535.79%
Divi's Laboratories Ltd.-0.43%85.44%58.15%496.33%1,610.60%10,946.76%

Performance & Financial Health Analysis: Jagsonpal Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricJAGSNPHARMDIVISLAB
Market Information
Market Cap i₹13.59B₹1.69T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i263,853253,443
90 Day Avg. Volume i325,105283,911
Last Close₹213.10₹6,608.50
52 Week Range₹155.00 - ₹301.65₹5,636.50 - ₹7,071.50
% from 52W High-29.36%-6.55%
All-Time High₹328.04 (Nov 25, 2024)₹7,071.50 (Jul 08, 2025)
% from All-Time High-35.04%-6.55%
Growth Metrics
Quarterly Revenue Growth-0.02%0.12%
Quarterly Earnings Growth-0.66%-0.01%
Financial Health
Profit Margin (TTM) i0.15%0.24%
Operating Margin (TTM) i0.19%0.30%
Return on Equity (TTM) i0.23%0.15%
Debt to Equity (MRQ) i3.500.58
Cash & Liquidity
Book Value per Share (MRQ)₹37.80₹580.95
Cash per Share (MRQ)₹24.28₹122.95
Operating Cash Flow (TTM) i₹532.93M₹19.67B
Levered Free Cash Flow (TTM) i₹553.61M₹21.91B
Dividends
Last 12-Month Dividend Yield i1.01%0.91%
Last 12-Month Dividend i₹2.50₹60.00

Valuation & Enterprise Metrics Analysis: Jagsonpal Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricJAGSNPHARM (Apr 24, 2026)DIVISLAB (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i33.3467.11
Forward P/E iN/A53.75
PEG Ratio i-0.514.63
Price to Sales (TTM) i4.8316.18
Price to Book (MRQ) i5.3410.82
Market Capitalization
Market Capitalization i₹13.59B₹1.69T
Enterprise Value i₹11.62B₹1.64T
Enterprise Value Metrics
Enterprise to Revenue i4.1315.86
Enterprise to EBITDA i20.2048.63
Risk & Other Metrics
Beta i-0.470.19
Book Value per Share (MRQ) i₹37.80₹580.95

Financial Statements Comparison: Jagsonpal Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricJAGSNPHARM (2025)DIVISLAB (2025)
Revenue/Sales i2.69B93.25B
Cost of Goods Sold i966.68M38.70B
COGS % of Revenue i36.0%41.5%
Gross Profit i1.72B54.55B
Gross Margin i64.0%58.5%
Research & Development iN/A270.00M
Operating Income (EBIT) i429.40M25.71B
Operating Margin i16.0%27.6%
EBITDA i591.61M33.19B
EBITDA Margin i22.0%35.6%
Pre-Tax Income i698.59M29.16B
Pre-Tax Income % of Revenue i26.0%31.3%
Income Tax i144.98M7.25B
Income Tax % of Revenue i5.4%7.8%
Net Income (Profit) i553.61M21.91B
Profit Margin i20.6%23.5%

Balance Sheet & Liquidity Metrics

MetricJAGSNPHARM (2025)DIVISLAB (2025)
Cash & Equivalents i112.15M4.15B
Total Current Assets i1.61B100.81B
Total Current Assets % of Revenue i60.0%108.1%
Total Current Liabilities i259.04M14.52B
Total Current Liabilities % of Revenue i9.6%15.6%
Long-Term Debt i76.32M20.00M
Long-Term Debt % of Revenue i2.8%0.0%
Total Shareholders Equity i2.40B149.69B
Retained Earnings i1.49B134.00B
Retained Earnings % of Revenue i55.4%143.7%
Property, Plant & Equipment i82.26M3.19B

Cash Flow Statement Comparison

MetricJAGSNPHARM (2025)DIVISLAB (2025)
Operating Cash Flow i532.93M19.67B
Operating Cash Flow % of Revenue i19.8%21.1%
Capital Expenditures i353.70M-14.38B
Free Cash Flow i549.52M2.15B
FCF Margin i20.4%2.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricJAGSNPHARMDIVISLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i67.14M265.47M
Float Shares i16.16M117.72M
% Held by Insiders i75.35%52.04%
% Held by Institutions i2.69%28.65%
% Held by Public i21.96%19.31%

Dividend Analysis & Yield Comparison: Jagsonpal Pharmaceuticals Ltd. vs Divi's Laboratories Ltd.

MetricJAGSNPHARMDIVISLAB
Last 12-Month Dividend i₹2.50₹60.00
Last 12-Month Dividend Yield i1.01%0.91%
3-Year Avg Annual Dividend i₹1.37₹50.00
3-Year Avg Dividend Yield i0.66%0.70%
3-Year Total Dividends i₹4.10₹150.00
Ex-Dividend DateSep 12, 2025Jul 25, 2025